François Javaudin1, Jean-Baptiste Lascarrou2, Quentin Le Bastard3, Quentin Bourry4, Chloé Latour4, Hugo De Carvalho4, Philippe Le Conte4, Joséphine Escutnaire5, Hervé Hubert5, Emmanuel Montassier3, Brice Leclère6. 1. Department of Emergency Medicine, University Hospital of Nantes, France; Microbiotas, Hosts, Antibiotics, and Bacterial Resistances (MiHAR), University of Nantes, Nantes, France. Electronic address: francois.javaudin@chu-nantes.fr. 2. Medical ICU, University Hospital of Nantes, Nantes, France. 3. Department of Emergency Medicine, University Hospital of Nantes, France; Microbiotas, Hosts, Antibiotics, and Bacterial Resistances (MiHAR), University of Nantes, Nantes, France. 4. Department of Emergency Medicine, University Hospital of Nantes, France. 5. Public Health Department EA 2694, University of Lille, Lille University Hospital, Lille, France. 6. Microbiotas, Hosts, Antibiotics, and Bacterial Resistances (MiHAR), University of Nantes, Nantes, France; Department of Epidemiology and Medical Evaluation, University Hospital of Nantes, Nantes, France.
Abstract
BACKGROUND: Pulmonary embolism (PE) represents 2% to 5% of all causes of out-of-hospital cardiac arrest (OHCA) and is associated with extremely unfavorable prognosis. In PE-related OHCA, inconsistent data showed that thrombolysis during cardiopulmonary resuscitation may favor survival. METHODS: This was a retrospective, observational, multicenter study from July 2011 to March 2018. All adults with OHCA, treated by a mobile ICU and with a diagnosis of PE confirmed on hospital admission, were included. The primary end point was 30-day survival in a weighted population. RESULTS: Of the 14,253 patients admitted to hospitals, 328 had a final diagnosis of PE and 246 were included in the analysis. In the group that received thrombolysis during resuscitation (n = 58), 14 (24%) received alteplase, 43 (74%) received tenecteplase, and one (2%) received streptokinase. Thirty-day survival was higher in the thrombolysis group than in the control group (16% vs 6%; P = .005; adjusted log-rank test) but the good neurologic outcome was not significantly different (10% vs 5%; adjusted relative risk, 1.97; 95% CI, 0.70-5.56). Median duration of stay in the ICU was 1 (0-5) day for the thrombolysis group and 1 (0-3) day for the control group (P = .23). CONCLUSIONS: In patients with OHCA with confirmed PE and admitted with recuperation of spontaneous circulation in the hospital, there was significantly higher 30-day survival in those who received thrombolysis during cardiopulmonary resuscitation compared with patients who did not receive thrombolysis.
BACKGROUND:Pulmonary embolism (PE) represents 2% to 5% of all causes of out-of-hospital cardiac arrest (OHCA) and is associated with extremely unfavorable prognosis. In PE-related OHCA, inconsistent data showed that thrombolysis during cardiopulmonary resuscitation may favor survival. METHODS: This was a retrospective, observational, multicenter study from July 2011 to March 2018. All adults with OHCA, treated by a mobile ICU and with a diagnosis of PE confirmed on hospital admission, were included. The primary end point was 30-day survival in a weighted population. RESULTS: Of the 14,253 patients admitted to hospitals, 328 had a final diagnosis of PE and 246 were included in the analysis. In the group that received thrombolysis during resuscitation (n = 58), 14 (24%) received alteplase, 43 (74%) received tenecteplase, and one (2%) received streptokinase. Thirty-day survival was higher in the thrombolysis group than in the control group (16% vs 6%; P = .005; adjusted log-rank test) but the good neurologic outcome was not significantly different (10% vs 5%; adjusted relative risk, 1.97; 95% CI, 0.70-5.56). Median duration of stay in the ICU was 1 (0-5) day for the thrombolysis group and 1 (0-3) day for the control group (P = .23). CONCLUSIONS: In patients with OHCA with confirmed PE and admitted with recuperation of spontaneous circulation in the hospital, there was significantly higher 30-day survival in those who received thrombolysis during cardiopulmonary resuscitation compared with patients who did not receive thrombolysis.
Authors: Ahmed K Pasha; Muhammad Umer Siddiqui; Muhammad Danial Siddiqui; Adnan Ahmed; Ammar Abdullah; Irbaz Riaz; M Hassan Murad; Haraldur Bjarnason; Waldemar E Wysokinski; Robert D McBane Journal: J Thromb Thrombolysis Date: 2021-08-31 Impact factor: 2.300
Authors: Omar A Alshaya; Abdulrahman I Alshaya; Hisham A Badreldin; Sarah T Albalawi; Sarah T Alghonaim; Majed S Al Yami Journal: Res Pract Thromb Haemost Date: 2022-06-17
Authors: Caspar Epstein Henriksson; Johanna Frithiofsson; Samuel Bruchfeld; Emma Bendz; Maria Bruzelius; Therese Djärv Journal: Resusc Plus Date: 2021-11-01
Authors: Jasmeet Soar; Bernd W Böttiger; Pierre Carli; Keith Couper; Charles D Deakin; Therese Djärv; Carsten Lott; Theresa Olasveengen; Peter Paal; Tommaso Pellis; Gavin D Perkins; Claudio Sandroni; Jerry P Nolan Journal: Notf Rett Med Date: 2021-06-08 Impact factor: 0.826
Authors: Carsten Lott; Anatolij Truhlář; Anette Alfonzo; Alessandro Barelli; Violeta González-Salvado; Jochen Hinkelbein; Jerry P Nolan; Peter Paal; Gavin D Perkins; Karl-Christian Thies; Joyce Yeung; David A Zideman; Jasmeet Soar Journal: Notf Rett Med Date: 2021-06-10 Impact factor: 0.826
Authors: Jasmeet Soar; Katherine M Berg; Lars W Andersen; Bernd W Böttiger; Sofia Cacciola; Clifton W Callaway; Keith Couper; Tobias Cronberg; Sonia D'Arrigo; Charles D Deakin; Michael W Donnino; Ian R Drennan; Asger Granfeldt; Cornelia W E Hoedemaekers; Mathias J Holmberg; Cindy H Hsu; Marlijn Kamps; Szymon Musiol; Kevin J Nation; Robert W Neumar; Tonia Nicholson; Brian J O'Neil; Quentin Otto; Edison Ferreira de Paiva; Michael J A Parr; Joshua C Reynolds; Claudio Sandroni; Barnaby R Scholefield; Markus B Skrifvars; Tzong-Luen Wang; Wolfgang A Wetsch; Joyce Yeung; Peter T Morley; Laurie J Morrison; Michelle Welsford; Mary Fran Hazinski; Jerry P Nolan Journal: Resuscitation Date: 2020-10-21 Impact factor: 5.262
Authors: Jerry P Nolan; Ian Maconochie; Jasmeet Soar; Theresa M Olasveengen; Robert Greif; Myra H Wyckoff; Eunice M Singletary; Richard Aickin; Katherine M Berg; Mary E Mancini; Farhan Bhanji; Jonathan Wyllie; David Zideman; Robert W Neumar; Gavin D Perkins; Maaret Castrén; Peter T Morley; William H Montgomery; Vinay M Nadkarni; John E Billi; Raina M Merchant; Allan de Caen; Raffo Escalante-Kanashiro; David Kloeck; Tzong-Luen Wang; Mary Fran Hazinski Journal: Resuscitation Date: 2020-10-21 Impact factor: 6.251